Cargando…

Disease burden of liver cancer in China from 1997 to 2016: an observational study based on the Global Burden of Diseases

OBJECTIVE: To evaluate the trends in disease burden and the epidemiological features of liver cancer in China while identifying potential strategies to lower the disease burden. DESIGN: Observational study based on the Global Burden of Diseases. PARTICIPANTS: Data were publicly available and de-iden...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Cheng, Fu, Xiaofang, Zhou, Yuqing, Liu, Xiaoxiao, Wu, Jie, Huang, Chenyang, Deng, Min, Li, Yiping, Li, Lanjuan, Yang, Shigui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500226/
https://www.ncbi.nlm.nih.gov/pubmed/31015269
http://dx.doi.org/10.1136/bmjopen-2018-025613
_version_ 1783415907034333184
author Ding, Cheng
Fu, Xiaofang
Zhou, Yuqing
Liu, Xiaoxiao
Wu, Jie
Huang, Chenyang
Deng, Min
Li, Yiping
Li, Lanjuan
Yang, Shigui
author_facet Ding, Cheng
Fu, Xiaofang
Zhou, Yuqing
Liu, Xiaoxiao
Wu, Jie
Huang, Chenyang
Deng, Min
Li, Yiping
Li, Lanjuan
Yang, Shigui
author_sort Ding, Cheng
collection PubMed
description OBJECTIVE: To evaluate the trends in disease burden and the epidemiological features of liver cancer in China while identifying potential strategies to lower the disease burden. DESIGN: Observational study based on the Global Burden of Diseases. PARTICIPANTS: Data were publicly available and de-identified and individuals were not involved. MEASUREMENT AND METHODS: To measure the liver cancer burden, we extracted data from the Global Health Data Exchange using the metrics of prevalence, incidence, mortality and disability-adjusted life years (DALYs). Joinpoint and negative binomial regressions were applied to identify trends and risk factors. RESULTS: From 1997 to 2016, the prevalence, incidence, mortality and DALYs of liver cancer in China were from 28.22/100 000 to 60.04/100 000, from 27.33/100 000 to 41.40/100 000, from 27.40/100 000 to 31.49/100 000 and from 10 311 308 to 11 539 102, respectively. The prevalence, incidence and mortality were increasing, with the average annual percent changes (AAPCs) of 4.0% (95% CI 3.9% to 4.2%), 2.1% (95% CI 2.0% to 2.2%) and 0.5% (95% CI 0.2% to 0.9%), respectively. Meanwhile, the rate of DALYs was stable with the AAPCs of −0.1% (95% CI −0.4% to 0.3%). The mortality-to-incidence ratio of liver cancer decreased from 1.00 in 1997 to 0.76 in 2016 (β=−0.014, p<0.0001). Males (OR: 2.98, 95% CI 2.68 to 3.30 for prevalence, OR: 2.45, 95% CI 2.21 to 2.71 for incidence) and the elderly individuals (OR: 1.57, 95% CI 1.55 to 1.59 for prevalence, OR: 1.58, 95% CI 1.56 to 1.60 for incidence) had a higher risk. Hepatitis B accounted for the highest proportion of liver cancer cases (55.11%) and deaths (54.13%). CONCLUSIONS: The disease burden of liver cancer continued to increase in China with viral factors as one of the leading causes. Strategies such as promoting hepatitis B vaccinations, blocking the transmission of hepatitis C and reducing alcohol consumption should be prioritised.
format Online
Article
Text
id pubmed-6500226
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-65002262019-05-21 Disease burden of liver cancer in China from 1997 to 2016: an observational study based on the Global Burden of Diseases Ding, Cheng Fu, Xiaofang Zhou, Yuqing Liu, Xiaoxiao Wu, Jie Huang, Chenyang Deng, Min Li, Yiping Li, Lanjuan Yang, Shigui BMJ Open Epidemiology OBJECTIVE: To evaluate the trends in disease burden and the epidemiological features of liver cancer in China while identifying potential strategies to lower the disease burden. DESIGN: Observational study based on the Global Burden of Diseases. PARTICIPANTS: Data were publicly available and de-identified and individuals were not involved. MEASUREMENT AND METHODS: To measure the liver cancer burden, we extracted data from the Global Health Data Exchange using the metrics of prevalence, incidence, mortality and disability-adjusted life years (DALYs). Joinpoint and negative binomial regressions were applied to identify trends and risk factors. RESULTS: From 1997 to 2016, the prevalence, incidence, mortality and DALYs of liver cancer in China were from 28.22/100 000 to 60.04/100 000, from 27.33/100 000 to 41.40/100 000, from 27.40/100 000 to 31.49/100 000 and from 10 311 308 to 11 539 102, respectively. The prevalence, incidence and mortality were increasing, with the average annual percent changes (AAPCs) of 4.0% (95% CI 3.9% to 4.2%), 2.1% (95% CI 2.0% to 2.2%) and 0.5% (95% CI 0.2% to 0.9%), respectively. Meanwhile, the rate of DALYs was stable with the AAPCs of −0.1% (95% CI −0.4% to 0.3%). The mortality-to-incidence ratio of liver cancer decreased from 1.00 in 1997 to 0.76 in 2016 (β=−0.014, p<0.0001). Males (OR: 2.98, 95% CI 2.68 to 3.30 for prevalence, OR: 2.45, 95% CI 2.21 to 2.71 for incidence) and the elderly individuals (OR: 1.57, 95% CI 1.55 to 1.59 for prevalence, OR: 1.58, 95% CI 1.56 to 1.60 for incidence) had a higher risk. Hepatitis B accounted for the highest proportion of liver cancer cases (55.11%) and deaths (54.13%). CONCLUSIONS: The disease burden of liver cancer continued to increase in China with viral factors as one of the leading causes. Strategies such as promoting hepatitis B vaccinations, blocking the transmission of hepatitis C and reducing alcohol consumption should be prioritised. BMJ Publishing Group 2019-04-23 /pmc/articles/PMC6500226/ /pubmed/31015269 http://dx.doi.org/10.1136/bmjopen-2018-025613 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Epidemiology
Ding, Cheng
Fu, Xiaofang
Zhou, Yuqing
Liu, Xiaoxiao
Wu, Jie
Huang, Chenyang
Deng, Min
Li, Yiping
Li, Lanjuan
Yang, Shigui
Disease burden of liver cancer in China from 1997 to 2016: an observational study based on the Global Burden of Diseases
title Disease burden of liver cancer in China from 1997 to 2016: an observational study based on the Global Burden of Diseases
title_full Disease burden of liver cancer in China from 1997 to 2016: an observational study based on the Global Burden of Diseases
title_fullStr Disease burden of liver cancer in China from 1997 to 2016: an observational study based on the Global Burden of Diseases
title_full_unstemmed Disease burden of liver cancer in China from 1997 to 2016: an observational study based on the Global Burden of Diseases
title_short Disease burden of liver cancer in China from 1997 to 2016: an observational study based on the Global Burden of Diseases
title_sort disease burden of liver cancer in china from 1997 to 2016: an observational study based on the global burden of diseases
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500226/
https://www.ncbi.nlm.nih.gov/pubmed/31015269
http://dx.doi.org/10.1136/bmjopen-2018-025613
work_keys_str_mv AT dingcheng diseaseburdenoflivercancerinchinafrom1997to2016anobservationalstudybasedontheglobalburdenofdiseases
AT fuxiaofang diseaseburdenoflivercancerinchinafrom1997to2016anobservationalstudybasedontheglobalburdenofdiseases
AT zhouyuqing diseaseburdenoflivercancerinchinafrom1997to2016anobservationalstudybasedontheglobalburdenofdiseases
AT liuxiaoxiao diseaseburdenoflivercancerinchinafrom1997to2016anobservationalstudybasedontheglobalburdenofdiseases
AT wujie diseaseburdenoflivercancerinchinafrom1997to2016anobservationalstudybasedontheglobalburdenofdiseases
AT huangchenyang diseaseburdenoflivercancerinchinafrom1997to2016anobservationalstudybasedontheglobalburdenofdiseases
AT dengmin diseaseburdenoflivercancerinchinafrom1997to2016anobservationalstudybasedontheglobalburdenofdiseases
AT liyiping diseaseburdenoflivercancerinchinafrom1997to2016anobservationalstudybasedontheglobalburdenofdiseases
AT lilanjuan diseaseburdenoflivercancerinchinafrom1997to2016anobservationalstudybasedontheglobalburdenofdiseases
AT yangshigui diseaseburdenoflivercancerinchinafrom1997to2016anobservationalstudybasedontheglobalburdenofdiseases